Better cardiovascular health Studies have shown that semaglutide treatment can also reduce the risk of cardiovascular events, which is particularly important for men with type 2 diabetes
Clinical implications of the trial outcomes for weight management Across the STEP trials, onceweekly subcutaneous semaglutide 2.4 mg demonstrated mean weight loss of 14.9%17.4% at 68 weeks in participants without diabetes with the mean baseline weight of 100107 kg, 38 , 40 , 41 , 43 offering the potential for clinically relevant improvement for individuals with obesityrelated diseases
The risk of death from any cause was 20% lower in the semaglutide group than in the placebo group (227 vs
Everyone is different, so dosing can be adjusted until you get the desired results
Why is refrigeration necessary
Olive oil, avocado, nuts, seeds, and fatty fish are excellent choices